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ABSTRACT
In recent years, the focus of attention in our understanding of pharmacokinetic antifungal drug efficacy
has expanded from the vascular to the tissue compartment, since for moulds in particular, this is the
primary point of encounter between the invading fungus and the host. Liposomal amphotericin B (LAB)
accumulates in the reticulo-endothelial system and other tissues for several weeks after systemic
administration at concentrations exceeding the MICs for many pathogenic fungi. Animal models
demonstrate that such tissue depots provide effective prophylaxis and even therapeutic opportunities
when LAB is given in high intermittent doses. Efficacy has been shown for even a single high dose of
LAB. Human studies have also confirmed retention of amphotericin B in tissues well beyond the last
administered dose. Clinical evidence has begun to accrue that suggests prophylactic efficacy in high-risk
patients with haematological malignancies who have received intermittent LAB. In an exploratory study
of patients with persistent and protracted neutropenic fever, one dose of 10 mg ⁄kg, followed by two
doses of 5 mg ⁄ kg given on days 1, 3 and 6, respectively, appeared to be as effective as the standard
regimen of 3 mg ⁄kg ⁄day given for a longer period. Serum kinetics suggest a large-volume deep tissue
compartment for LAB. The drug also appears to accumulate in the tissue, as reflected by bone marrow
concentrations. These early observations suggest the potential for intermittent high dosing of LAB for
prophylaxis and management of invasive fungal infections, thus providing an alternative option to more
frequent and expensive administration of LAB, and daily administration of azoles or candins. This
might offer the benefits of lower treatment costs, improved patient compliance and reduced toxicity.
Further clinical studies are required to confirm the feasibility of such an approach.
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MAJOR ANTIFUNGAL DRUGS
The major current monotherapeutic options for
antifungal drug management are amphotericin B,
fluconazole, voriconazole and candins. The pre-
ferred drug in terms of efficacy and safety is a
matter of considerable debate, not least because of
the heterogeneity of patients, endpoint definitions
and interpretations encountered in the different
randomised clinical trials and some incongruous
findings, such as the <10% response rate for
invasive aspergillosis to amphotericin B in one
recent study [1]. These issues have been discussed
recently [2]. Notwithstanding limitations, ampho-
tericin B, particularly in its liposomal formula-
tion, is at least as good an alternative drug as
voriconazole and caspofungin. Liposomal
amphotericin B (LAB, AmBisome, Gilead
Sciences, Sandimas, CA, USA) uniformly has
fungicidal activity, causes relatively few course-
terminating adverse drug events, leads to a low
incidence of emergent resistant organisms and
has a wide spectrum of fungal species coverage.
The limited adverse event profile is superior to
that of conventional amphotericin B (CAB); tox-
icity-related events are significantly reduced [3]
and associated survival advantages have been
documented [4]. One review has called for LAB as
the ‘new gold standard’ [5]. The lipid formulation
Abelcet (amphotericin B lipid complex (ABLC))
has a toxicity profile similar to CAB, indicating
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the profound differences that exist between the
lipid formulations [6].
SETTING OF PROTRACTED
NEUTROPENIC FEVER
The haematological patient with fever and pro-
tracted, severe neutropenia with unexplained
clinical and microbiological cause of the fever is
at high risk for an invasive fungal infection (IFI).
Addition of CAB to the therapy for such patients,
supplementing broad-spectrum antibiotic cover-
age, has been shown to significantly reduce overt
IFI [7,8]. However, it is necessary to treat approx-
imately ten patients to prevent one IFI event [8],
amphotericin B is toxic, (LAB still carries c. 15%
risk of nephrotoxicity) and LAB has high acqui-
sition costs. This blunderbus approach has rightly
attracted criticism [9]. However, not only does
identification of that subgroup of patients involve
highly intensive diagnostics, but application of
existing serological methodologies requires much
more clinical validation before they can be uni-
versally applied. For example, the galactomannan
test is only moderately sensitive, detects only
Aspergillus (<50% among the increasing diversity
of invasive fungi encountered) and has high inter-
centre variability in performance [10,11]. How-
ever, recent studies do support its use in the
clinical arena [12]. b-D-Glucan detects a wider
range of IFIs but is subject to false-positive
findings [13,14]. PCR testing also has limitations.
High-resolution computed tomography imaging
of the lungs to detect the ‘halo sign’, a virtually
pathognomonic marker for invasive pulmonary
aspergillosis (IPA) in this patient population, is
highly sensitive but is also expensive, and
requires early and repeated examinations to be
useful [15]. In the context of such diagnostic
limitations, an alternative or supplementary ap-
proach is to consider alternative dosing regimens
for LAB, particularly in the setting of antibiotic-
unresponsive neutropenic fever (AUNF) or pro-
phylaxis.
LIPOSOMAL AMPHOTERICIN B AND
DOSE RESPONSES
LAB has unique properties that are not seen with
the parent drug CAB. Doses of the order of 3–
5 mg ⁄ kg ⁄day are commonly used in clinical
practice without the attendant high frequency of
adverse reactions seen with CAB [3]. The unique
structure of LAB, with its complex bilayer drug-
encapsulating membrane, facilitates accumulation
of amphotericin B at sites of fungal infection [16],
where tissue phospholipases cleave amphoteri-
cin B [17], the drug then entering into macro-
phages and fungus-infected cells [18]. The drug is
effective at relatively low doses because of this
mechanism of cellular delivery. Yet there is
evidence of a dose-related therapeutic effect. In
a maximum-dose-finding study, dosages between
7.5 and 15 mg ⁄ kg ⁄day were administered [19].
The frequencies of infusion-related reactions
(chills, rigors, chest pain, dyspnoea), nephrotox-
icity (greater than or equal to a two-fold rise in
creatinine), hepatotoxicity and drug discontinua-
tion because of toxicity were not different
between the four different dosages given. The
maximum tolerated dose appeared to be in excess
of 15 mg ⁄ kg ⁄day. This study suggested a prag-
matic approach of high-dose administration of
LAB for managing patients with an IFI progress-
ing on lower, ‘standard’ doses. Animal models
and in-vitro studies confirm increased efficacy in
parallel with elevated doses [20,21]. Thus, Olson
et al. (2006) demonstrated that LAB accumulated
in (uninfected) murine lung tissue in a linear
fashion that was dependent on dosage and
number of doses administered [21] (Fig. 1a).
Immunosuppressed mice, when challenged in-
tra-nasally with Aspergillus fumigatus and then
treated with 15 or 20 mg ⁄ kg LAB for 3 days, had
a greater reduction in IFI fungal burden with the
higher doses (Fig. 1b). High survival rates of up to
90% were obtained, without significant nephro-
toxicity.
BLOOD COMPARTMENT KINETICS
AND RESPONSES
High AUC, high Cmax and non-linear pharmaco-
kinetics have been well-characterised for the
blood compartment in patients receiving LAB.
The in-vitro concentration-dependent activity of
amphotericin B indicates that maintaining blood
levels above the MIC for bloodstream IFIs would
be best achieved by administering high doses of
the drug, at least initially. This has been shown in
animal studies [22,23]. Furthermore, other anti-
fungal drugs such as caspofungin and itracona-
zole are given with initial high loading doses.
However, a recent clinical trial indicated that
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improved outcome in patients with IPA was not
achieved with higher (10 mg ⁄kg ⁄day) than with
lower (3 mg ⁄ kg ⁄day) doses of LAB [24].
The traditional understanding of the efficacy
of antifungal drugs has pivoted around peak
plasma concentration. A concentration-depen-
dent killing phenomenon for Candida has been
established for CAB. Thus, higher blood Cmax ⁄ -
MIC ratios, optimally 10.0, have been found to
be more therapeutically effective than strategies
that maximise overall drug exposure with high
AUC ⁄MIC ratios in Candida infection [22,23].
Recently, this was also established for IPA, when
the most effective Cmax ⁄MIC ratio was esta-
blished as 2.4 [22].
TISSUE CONCENTRATIONS
Another property of LAB is its ability to achieve
fungicidal concentrations in the reticulo-endothe-
lial and other tissues. This is of fundamental
importance in managing IFIs that have localised
to the key target organs of liver, spleen, kidney,
central nervous system and lung. It is clear that
antifungal drug activity varies with the infected
organ studied—for example, a higher dose of
CAB is required to achieve the same degree of
fungal burden reduction in the kidney than in the
lung [23]. This observation suggests that tissue
kinetics are important factors governing response.
However, the IPA animal models used may not
mimic the human situation [22].
Therefore, in recent years, the focus of
antimycotic activity has shifted from the blood
compartment to tissue sites of infection. Pragmat-
ically, it seems that the antifungal drug concen-
tration at actual tissue sites of fungal infection
may be as important as the peripheral kinetics.
This may be particularly important for those
fungal infections whose primary portal of entry
is extravascular, such as Aspergillus.
It is generally accepted that on a mg ⁄ kg basis
CAB is approximately five to ten times more
effective than LAB [23,24]. However, serum
kinetic studies clearly show that serum exposure
to LAB is substantially greater than that to CAB.
The Cmax and AUC values are 26-fold and eight-
fold more with LAB, while the elimination half-
life is 60% that of of CAB. This discrepancy
between serum kinetics and drug activity may be
explained by the more avid tissue binding that
occurs with CAB (c. five- to ten-fold more). In
addition, tissue kinetic studies demonstrate the
converse of the serum profile, namely a higher
tissue exposure to CAB than to LAB [23]. Thus,
AUC values for CAB, as compared to LAB, are
five-fold, four-fold and two-fold greater in the
kidney, liver and lung, respectively. In fact, the
ratio of organ LAB:CAB AUCs of effective doses
is similar, at 1:1. The major potential advantage of
LAB over CAB is therefore the possibility of
systemically administering higher doses
of amphotericin B as a liposomal formulation
without substantial dose treatment discontinua-
tions for nephrotoxicity, thus delivering higher
cumulative tissue concentrations in a shorter
period of time [25].
RETENTION OF AMPHOTERICIN B IN
TISSUES
Another pertinent observation is that LAB is
retained in tissues well beyond the final admin-
istered dose, raising the possibility of a tissue
depot for amphotericin B. Human data on this
are limited but clear. Seven patients who had
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Fig. 1. (a) Amphotericin B concentration in lungs after one
or four doses of LAB. (b) Fungal burden in lung tissue
in mice infected with Aspergillus fumigatus treated for
3 days.
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received LAB and 13 Amphocil for
suspected ⁄proven IFI, and who died from
multi-organ failure, had amphotericin B levels
measured by HPLC in specimens removed at
autopsy. Tissue levels, sampled at a mean time
of 16–36 h after the final dose of LAB ,varied
between11.63 mg ⁄ kginthe lungand102.81 mg ⁄ kg
in the liver. These exceeded the MIC90 values for
most Aspergillus (1–2 mg ⁄L) and Candida (0.25–
2.0) spp.. Furthermore, the concentrations of
amphotericin B in spleen, kidney, myocardium
and cerebral cortex were significantly correlated
with the cumulative dose of LAB given (r ‡0.88,
p <0.01) [26]. In 18 patients with lung cancer
undergoing lung resection, amphotericin B levels
in the serum and lung were measured over 24 h
following a 1-h single infusion of LAB
1.5 mg ⁄ kg. As the plasma amphotericin B con-
centration fell from 3.4 to 1.0 mg ⁄L between the
10th and 24th hour, lung concentrations pro-
gressively increased from 1.0 to 2.5 mg ⁄kg,
confirming lung tissue accumulation of the drug
[27]. Among haematological malignancy patients
with IFI, three patients who died among 116
receiving LAB for IFI had autopsy specimens
assayed for amphotericin B. For a mean cumu-
lative dose of 1716 mg (820–3428), the mean
lung concentration was 16.83 (0.55–45.79) mg ⁄ kg
[28]. In another autopsy study, 13 cancer
patients underwent tissue amphotericin B deter-
mination. Recovery in liver, spleen, lung and
kidney was correlated with the total cumulative
dose of CAB, and varied between 0.4 and
147.1 mg ⁄ kg tissue. The median duration be-
tween the last infusion and autopsy sampling
was 27 h. Fungistatic titres were observed and
linearly correlated with the amphotericin B con-
centration [29]. Finally, there have been some
previous reports that amphotericin B can be
recovered from tissues for up to 100 days fol-
lowing treatment completion [30].
However, there is a differential tissue distri-
bution of amphotericin B within a particular
organ, and this partly depends on the type of
lipid formulation of the drug. Groll et al. [31]
demonstrated that LAB concentrations in epi-
thelial lining fluid were between 2.5 and five
times higher than those of CAB, ABLC or
amphotericin B colloidal dispersion (ABCD).
However, pulmonary alveolar macrophage
concentrations were similar between the
amphotericin B preparations. Actual lung tissue
levels for LAB were lower than those of ABLC
but similar to those of ABCD and higher than
those of CAB. In airborne mould infections such
as IPA, the distal airways of the lung and
alveoli are important first contact sites with
phagocytes, and optimal tissue concentrations
are therefore important. Although the observa-
tions made by Groll and colleagues are impor-
tant, the therapeutic implications are currently
unknown.
TISSUE RETENTION OF
AMPHOTERICIN B AND RELATION
TO ANTIFUNGAL EFFICACY
Prophylaxis
The knowledge that amphotericin B accumulates
in the reticulo-endothelial system [32] and other
tissues following its administration opens the
possibility that such tissue depots might play a
role in the management of IFI in a variety of
settings. Several key animal studies have shown
that pre-administration of LAB is highly effective
in preventing IFI. Garcia et al. [33] challenged
immunosuppressed mice with Histoplasma capsul-
atum 7 days after admistering a single dose of
CAB or LAB at doses ranging from 1 to 20 mg ⁄ kg.
A single dose of either 10 or 20 mg ⁄kg LAB
resulted in sterilisation of the spleen by day 10
after challenge, and 100% of the animals sur-
vived, as compared to 20% of those in the control
group, which also had substantial organisms in
their tissue. At day 24, however, protection from
IFI had diminished, with a minority of the mice
now having the same infection. Survival was 60%
in the 10 mg ⁄ kg group and 80% in the 20 mg ⁄ kg
group. In a subsequent experiment using Candida
albicans, significant reductions in the kidney fun-
gal burden were documented with LAB at all
doses, as compared to the controls or to CAB
treatment, and the effect was proportional to the
dose of LAB used. Concentration determinations
of amphotericin B in the kidney and spleen at
7 days after the single administered dose showed
dose-dependent increasing accumulation of the
drug (Fig. 2a,b). Similar results were obtained in
immunocompetent mice. The findings therefore
demonstrate that a single high dose of LAB
accumulates in tissue for at least 7 days after
administration, at concentrations above the
MICs for most pathogenic fungi, and that this
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phenomenon correlates strongly with tissue anti-
fungal activity. However, the fact that in the
Histoplasma challenge model LAB did not result in
sustained, complete elimination of the organism
from the spleen reflects the importance of both
host response and of selective organ penetration
and accumulation of amphotericin B in determin-
ing successful eradication. This is because, in the
model used, cyclophosphamide disrupts T-cell
dysfunction, and hence elimination of Histoplasma
is not possible. In the Candida experiment,
although the IFI burden was reduced, it was not
eliminated completely, since LAB localises to
macrophages, whereas Candida replicates extra-
cellularly. The correlation between the concentra-
tion of amphotericin B in tissue and drug
prophylactic efficacy against Histoplasma was
greater than that seen for Candida, probably
because of the lower doses of LAB in the kidney
than in the spleen.
In another experiment, mice were given LAB at
either 2.4 mg ⁄ kg for 5 days per week for 5 weeks
or 15 mg ⁄ kg weekly for 4 weeks [25]. Amphoter-
icin B accumulated by rank order spleen >
liver > kidney > lung. In the spleen, there was
no difference in the tissue-accumulated ampho-
tericin B between the two regimens. At 3 weeks
post-treatment, there was c. 270–290 mg ⁄ kg
amphotericin B in the spleen, and this fell to
100–115 mg ⁄ kg at 6 weeks post-treatment.
Clearly, levels well in excess of fungal MICs were
seen in all tissues apart from the lung, which
showed undetectable levels until 3 weeks (corre-
sponding to a 180 mg ⁄ kg cumulative dose).
Reduction in tissue levels post-treatment de-
pended on the organ; for example, no reduction
between week 3 and week 6 was found in the
kidney. When a Candida glabrata challenge was
given at 1, 3 or 7 days after completion of a single
dose or two doses of LAB prophylaxis, there was
a significant reduction in fungal burden over all
days as compared with controls. There was a
dose-dependent association with the number of
kidneys free of C. glabrata. Similar findings were
seen with a C. albicans challenge. At both 3 and
6 weeks post-treatment, a significant drop in CFU
in the kidney was found, with no difference
between the regular daily or intermittent dosing
schedules. In the spleen, there was a significant
fall in fungal burden at 3 weeks with intermittent
dosing as compared to daily dosing, but not for
the 6-week time-point. Both regimens demon-
strated significant drops in CFU. These experi-
ments support the notion that high intermittent
dosing with LAB produces substantial, sustained
tissue (variable, depending on organ) accumula-
tion of amphotericin B, which has substantial
antifungal activity during subsequent fungal
challenge. (Fig. 3a,b).
Treatment
Evidence has also emerged that intermittent
dosing is as effective as regular daily dosing in
the definitive treatment of IFI. In a study of
immunocompromised mice infected intrave-
nously on day 2 with Candida and then given
variable doses of LAB intermittently, the follow-
ing sentinel observations were made [34]. A
higher cumulative dose given over the first 4 days
was more effective than a lower cumulative dose
given daily. The experiment showed that the
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Fig. 2. (a) Concentrations of amphotericin B in kidney of
immunosuppressed mice. (b) Concentrations of amphoter-
icin B in spleen of immunosuppressed mice.
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efficacy of treating an IFI can be sustained even
when the frequency of dosing of LAB is reduced
from the standard traditional approach of once-
daily. Even a single high dose of LAB was as
effective as daily dosing in reducing IFI. Further-
more, the therapeutic efficacy of such an inter-
mittent dosing approach is increased when the
doses administered are higher, at 20 mg ⁄ kg, and
particularly when the total cumulative dose
increases—after 5 weeks of intermittent high-
dose treatment with 20 mg ⁄ kg (cumulative
300 mg ⁄kg), the tissues examined are sterile as
compared to controls, in which log10 7.5 CFU are
found (Fig. 4).
HUMAN STUDIES
Kinetics and safety
Several human studies have also investigated
intermittent dosing, and have supported the
feasibility of an intermittent dosing approach to
prophylaxis and treatment. This may be particu-
larly relevant in the setting of AUNF, due to
cryptic IFI, where the fungal burden will, by
definition, be low, but the possibility of low-
density fungal dissemination might be presumed.
The occurrence of glucanaemia without overt IFI
in patients with severe entero-mucositis supports
this (Ellis, unpublished data; Fig. 5). The admin-
istration of intermittent amphotericin B in such
patients might provide an alternative manage-
ment option while simultaneously reducing total
drug exposure and thereby limiting nephrotoxi-
city, other adverse reactions and costs.
A safety study concentrated particularly on at-
risk patients—those receiving reduced-intensity
conditioning allogeneic stem-cell transplantation
[35]. They received high-dose (7.5 mg ⁄ kg) weekly
LAB prophylaxis. Twenty-nine per cent of 21
patients had infusion-related reactions, and 33%
of patients had treatment discontinued because of
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severe reactions, including creatinine rise
>1.5 times baseline, hypotension and violent chest
pain—all of which resolved spontaneously. The
median percentage variation in serum creatinine
over the LAB administration period was
15% ± 12%. Despite the notable adverse reac-
tions, the data did provide support for undertak-
ing an efficacy study.
The study of Mehta et al. generated important
but limited paediatric data [36]. This was a
kinetics study in which 10 mg ⁄ kg LAB was given
weekly to 14 children undergoing stem-cell trans-
plantation for unusual congenital abnormalities
such as severe combined immunodeficiency or
Fanconi’s anaemia. There were no significant
adverse changes in creatinine, potassium, magne-
sium or liver enzymes. This is in keeping with
paediatric experience for other polyene formula-
tions. One week after the first infusion and after
the fourth weekly infusion, the plasma concen-
trations remained around the MICs for most
susceptible strains of Candida and Aspergillus
spp. that are likely to be encountered. The data
support the feasibility of administering weekly
high-dose LAB safely to children as an alternative
antifungal strategy to long-term azole prophy-
laxis, which carries the risk of liver toxicity, or
caspofungin, which needs daily administration.
Another human safety study was performed by
Cordonier and colleagues [37]. A single weekly
high dose (10 mg ⁄ kg) of LAB was given to 15
patients undergoing first induction chemotherapy
or 15 patients undergoing dose consolidation
chemotherapy or allogeneic stem-cell transplan-
tation (for 8–12 weeks, depending on the presence
of acute graft vs. host disease). Five of 23 patients
(21.7%) had infusion-related reactions, and 7 ⁄ 23
(30.4%) had rises in creatinine >1.5 times base-
line. Treatment was discontinued in five of eight
patients (62.5%) in the transplant group because
of toxicity. Although efficacy was not a primary
outcome, it was mentioned that fever of unknown
origin occurred in c. half of all patients, and an IFI
in 17%. The timing of the LAB prophylaxis in the
transplant group remains to be determined.
Feasibility and efficacy
An early study was that of Kelsey et al. [38]. In a
randomised, blinded, placebo-controlled clinical
trial, LAB at 2 mg ⁄ kg three-times-weekly as
prophylaxis, from the start of chemotherapy until
neutropenia resolution, was compared to placebo.
Among 161 patients studied, a proven IFI devel-
oped in only 3 ⁄ 87 patients—all on placebo.
However, suspected IFI, defined as AUNF,
occurred in 31 ⁄ 74 patients receiving LAB
(41.9%) vs. 40 ⁄ 87 receiving placebo (46%) (dif-
ference not significant). Fungal colonisation in the
LAB arm was half that in the placebo arm (15 ⁄ 74
(20.2%) vs. 35 ⁄ 87 (40.2%)) (p <0.01). The failure
of this study to show a significant protective effect
of LAB was due to the overall low incidence of
IFI, small sample size, lack of modern fungal
diagnostics and an inappropriate definition for
suspected IFI.
A neutropenic study compared LAB with
no systemic prophylaxis in patients who had
expected severe and protracted neutropenia
resulting from chemotherapy or who had under-
gone autologous stem-cell transplantation [39].
LAB was administered at a low dose of 50 mg on
alternate days. The European Organisation for
Research and Treatment of Cancer ⁄mycoses
study group (MSG) criteria were used to identify
prophylaxis failures. The group receiving LAB
had significantly fewer IFIs (particularly IPA)
overall (5 ⁄ 75–6.7% vs. 20 ⁄ 57–35%, p 0.001). Sec-
ondary endpoints indicated a significant reduc-
tion in idiopathic pneumonia (5.5% vs. 25.7%) as
well as superficial fungal infections and use of
antifungal treatment. Crude and IFI-related mor-
talities were reduced, but not significantly (1.8%
vs. 7.3%, p 0.07). The trial was limited by its open
design and bias from multiple patient re-entry.
However, the same degree of difference was
observed when analysis was confined to first
neutropenic event.
The final study is this authors’ work. The
design was a randomised clinical exploratory
trial in which patients received either standard
treatment (arm B) (3 mg ⁄ kg ⁄day) or intermittent
high dosage (arm A) (10 mg ⁄ kg day 1, 5 mg ⁄ kg
days 3 and 6) of LAB for AUNF. This feasibility
study addressed broad safety and efficacy trends
and collected data on kinetics. With use of a five-
point composite score, the success rates were 67%
and 66%, respectively. Similar specific failure
incidents occurred in each arm (Table 1). One
death was documented in arm A, due to a
combination of resistant haematological disease
and extensive progressive IPA present at baseline.
Days to defervescence were similar. The propor-
tions of patients who developed serology positive
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for an IFI were also similar in both arms. The
mean changes in serum creatinine concentrations
were also similar in the two study arms. Frequen-
cies of adverse drug events were 40% in arm B
and 47% in arm A, although there were rather
more patients in arm A with infusion-related
chills or rigors (40% vs. 27%). However, treat-
ment was not discontinued for any patient in
either dosing schedule because of toxicity. Blood
was sampled over selected days, and times of
LAB infusion and bone marrow were sampled
after the last infusion was completed, for bioassay
of amphotericin B. Using a two-compartment
model to fit the serum–time concentrations, the
Table 1. Efficacy
3 mg/kg/day
(Arm B)
10, 5, 5 mg/kg
(Arm A)
Enrolled, n 15 15
Success of ITT 10 ⁄ 15 (67%) 10 ⁄ 15 (67%)
Failure of baseline IFI to respond 0 0
Failure to defervesce 1 2
Discontinuation of treatment 1 2c
Breakthrough IFI 3d 0
Death 0 1e
Success of modified ITT 13 ⁄ 14 (93%)a 11 ⁄ 14 (79%)b
Days to defervescence 8.4 ± 6.1 (2–20) 8.8 ± 5.1 (2–19)
Patients developing positive serology 3 ⁄ 11 (27%) 4 ⁄ 14 (28%)
ITT, intention to treat; IFI, invasive fungal infection.
aNeutropenia resolved at day of study entry.
bOne patient with extensive probable IPA diagnosed after study entry.
cGiven other antifungals because of defervescence failure.
dTwo probable + one possible IPA.
eProbable IPA (same patient as in b).
Table 2. Comparison of population pharmacokinetic parameters from the two arms
Arm A Arm B
Population
mean
estimate
SEa
(% CV)
Inter-individual
variabilityb
(% CV)
Population
mean
estimate
SEa
(% CV)
Inter-individual
variabilityb
(% CV)
Age (years) 36.3 ± 14 36 ± 11
Weight (kg) 66.5 ± 16 66.3 ± 17.5
V1 (L) 258 11.24 32.09 6.17 30.31 126.1
V2 (L) 3100 47.74 31.16 157 6.62 14.56
Clearance (L ⁄h) 2.46 23.37 56.92 4.72 10.74 23.15
Total AUC (mgÆh ⁄L) (±SD) 236 ± 64.7 541 ± 163
Total AmBisome dose (mg) (±SD) 1328 ± 358 2732 ± 723
AUC drug dose normalised
(mgÆh ⁄L ⁄mg)
0.178 0.198
V1, central compartments; V2, peripheral compartments.
aCoefficient of variation of the estimates (100 · SE estimate ⁄ estimate).
bEstimates of variability expressed as approximate percentage coefficient of variation (% CV, 100 W).
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Fig. 6. Bone marrow concentrations of amphotercin B.
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central and peripheral compartments were strik-
ingly larger than in previously published studies
(Table 2). This may be partially explained by the
prolonged sampling time of 400 h, and the high
peripheral compartments (V2) may indicate a
deep compartment for the drug. Clearance and
AUC parameters were lower in arm A, but when
the figures were normalised for total LAB given,
they were similar. The reduced total serum
exposure of the drug in arm A offers the possi-
bility of reduced toxicity. Amphotericin B con-
centrations in the bone marrow varied widely
among patients (Fig. 6). However, antifungal
activity could still be detected in the marrow for
up to 7 days after the last infusion in arm A.
Values as high as 3.2 mg ⁄L were documented.
The study confirms the feasibility of administer-
ing high initial and then intermittent doses of
LAB safely to patients with haematological malig-
nancy undergoing chemotherapy and who devel-
op AUNF. These initial, limited data suggest that
such an approach may provide similar efficacy as
a more standard dosing regimen but with sub-
stantial savings in drug costs and administration.
This hypothesis should be tested in a larger
clinical trial.
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